Eculizumab Treatment for Rescue of Renal Function in IgA Nephropathy

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2014 Jun 14

PMID 24924752

Citations 51

Authors

Therese Rosenblad

Johan Rebetz

Martin Johansson

Zivile Bekassy

Lisa Sartz

Diana Karpman

Affiliations

Soon will be listed here.

Abstract

Background: Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure.

Case Diagnosis/treatment: We describe the clinical course of an adolescent with rapidly progressive disease leading to renal failure in spite of immunosuppressive treatment. Due to refractory disease the patient was treated with eculizumab (anti-C5) for 3 months in an attempt to rescue renal function. Treatment led to clinical improvement with stabilization of the glomerular filtration rate and reduced proteinuria. Discontinuation of treatment led to a rapid deterioration of renal function. This was followed by a single dose of eculizumab, which again reduced creatinine levels temporarily.

Conclusions: Early initiation of eculizumab therapy in patients with progressive IgA nephropathy may have a beneficial effect by blocking complement-mediated renal inflammation.

Citing Articles

The road ahead: emerging therapies for primary IgA nephropathy.

Filippone E, Gulati R, Farber J Front Nephrol. 2025; 5:1545329.

PMID: 39968279 PMC: 11832374. DOI: 10.3389/fneph.2025.1545329.

Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.

Drugs in Development to Treat IgA Nephropathy.

Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F Drugs. 2024; 84(5):503-525.

PMID: 38777962 DOI: 10.1007/s40265-024-02036-1.

Systematic Review of the Link Between Oxford MEST-C Classification and Complement Activation in IgA Nephropathy.

Stefan G, Alamartine E, Mariat C, Maillard N Kidney Int Rep. 2024; 9(2):356-369.

PMID: 38344730 PMC: 10851005. DOI: 10.1016/j.ekir.2023.11.005.

Targeting complement in IgA nephropathy.

Caravaca-Fontan F, Gutierrez E, Sevillano A, Praga M Clin Kidney J. 2023; 16(Suppl 2):ii28-ii39.

PMID: 38053977 PMC: 10695513. DOI: 10.1093/ckj/sfad198.

References

Schmitt R, Krmar R, Kristoffersson A, Soderberg M, Karpman D . IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr. 2010; 170(1):107-10. DOI: 10.1007/s00431-010-1279-3. View

Edey M, Strain L, Ward R, Ahmed S, Thomas T, Goodship T . Is complement factor H a susceptibility factor for IgA nephropathy?. Mol Immunol. 2009; 46(7):1405-8. DOI: 10.1016/j.molimm.2008.12.002. View

Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M . Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol. 2011; 12:64. PMC: 3283454. DOI: 10.1186/1471-2369-12-64. View

Roos A, Rastaldi M, Calvaresi N, Oortwijn B, Schlagwein N, van Gijlswijk-Janssen D . Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17(6):1724-34. DOI: 10.1681/ASN.2005090923. View

Kim S, Koo H, Lim B, Oh H, Yoo D, Shin D . Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One. 2012; 7(7):e40495. PMC: 3391269. DOI: 10.1371/journal.pone.0040495. View

Gharavi A, Kiryluk K, Choi M, Li Y, Hou P, Xie J . Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011; 43(4):321-7. PMC: 3412515. DOI: 10.1038/ng.787. View

Rauterberg E, Lieberknecht H, Wingen A, Ritz E . Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. 1987; 31(3):820-9. DOI: 10.1038/ki.1987.72. View

Tomana M, Matousovic K, Julian B, Radl J, Konecny K, Mestecky J . Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997; 52(2):509-16. DOI: 10.1038/ki.1997.361. View

Cattran D, Coppo R, Cook H, Feehally J, Roberts I, Troyanov S . The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5):534-45. DOI: 10.1038/ki.2009.243. View

10.

Kiryluk K, Novak J, Gharavi A . Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med. 2012; 64:339-56. PMC: 3921622. DOI: 10.1146/annurev-med-041811-142014. View

11.

Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R . Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol. 1984; 21(6):335-40. View

12.

Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D . C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol. 2009; 42(4):373-80. DOI: 10.1080/00365590801943241. View

13.

HIKI Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001; 59(3):1077-85. DOI: 10.1046/j.1523-1755.2001.0590031077.x. View

14.

Wyatt R, Kanayama Y, Julian B, Negoro N, Sugimoto S, Hudson E . Complement activation in IgA nephropathy. Kidney Int. 1987; 31(4):1019-23. DOI: 10.1038/ki.1987.101. View

15.

Watanabe S, Yamaguchi Y, Suzuki T, Ikezoe M, Matsumoto N, Chikamoto H . Inherited factor H dysfunction and complement-associated glomerulonephritis in renal grafts of first and second transplantations. Clin Transplant. 2002; 15 Suppl 5:45-50. DOI: 10.1034/j.1399-0012.2001.0150s5045.x. View